Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer

The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer (mCPRP). To contextualize the progression free s...

Full description

Bibliographic Details
Main Authors: Giuseppe Fallara, Daniele Robesti, Daniele Raggi, Francesco Montorsi, Andrea Necchi, Matthew R. Cooperberg, Bernard Malavaud, Guillaume Ploussard, Alberto Martini
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:European Urology Open Science
Subjects:
Prostate cancer
Overall survival
Progression-free survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323002033

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323002033

Similar Items